Geographic Atrophy Secondary to Age-Related Macular Degeneration study: RO7965032
Official title A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
ClinicalTrials.gov ID: NCT07851259
What this study is testing
What is RO7965032?
This is an investigational medicine being studied to treat geographic atrophy, a form of age-related macular degeneration.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether a new drug called RO7965032 works well. It also checks how safe the drug is for people with this eye condition.
- Who it's for
- You may be able to join if you have geographic atrophy from age-related macular degeneration.
- What's involved
- You would get the new drug. The team will check your eyes to see how the treatment works.
- Time commitment
- The source text does not say how long the study lasts or how many visits are needed.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Ocular for the Study Eye
- BCVA score of \>= 35 letters using the ETDRS VA chart at a starting distance of 4 meters
- Lesions may be either extrafoveal or subfoveal Ocular for Both Eyes
- Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
- Well-demarcated GA secondary to AMD
You likely can't join if
- General Exclusion Criteria - History of hypersensitivity, a severe allergic reaction or anaphylactic reaction to any component of the investigational...
- History of diabetic macular edema (DME), retinal vein occlusion, corneal transplant, retinal detachment, Stage 3 or 4 macular hole, optic neuropathy...
- Current or prior history of central serous retinopathy
- Aphakia or absence of the posterior capsule in the study eye Ocular Exclusion Criteria for the Non-Study Eye \- Non-functioning non-study eye defined...
- Proliferative diabetic retinopathy
- History of recurrent infectious or inflammatory ocular disease
See the full eligibility criteria
- Ocular for the Study Eye
- BCVA score of \>= 35 letters using the ETDRS VA chart at a starting distance of 4 meters
- Lesions may be either extrafoveal or subfoveal Ocular for Both Eyes
- Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
- Well-demarcated GA secondary to AMD
- General Exclusion Criteria - History of hypersensitivity, a severe allergic reaction or anaphylactic reaction to any component of the investigational drug injection Ocular Exclusion Criteria for the Study Eye
- History of diabetic macular edema (DME), retinal vein occlusion, corneal transplant, retinal detachment, Stage 3 or 4 macular hole, optic neuropathy, or retinal dystrophy
- Current or prior history of central serous retinopathy
- Aphakia or absence of the posterior capsule in the study eye Ocular Exclusion Criteria for the Non-Study Eye \- Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of...
- Proliferative diabetic retinopathy
- History of recurrent infectious or inflammatory ocular disease
- Current or prior history of choroidal neovascularization (CNV) in either eye
- Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye Other protocol-defined inclusion/exclusion criteria may apply
The study team makes the final eligibility decision.
Where it is enrolling
- Walnut Creek, California, United States
- Winston-Salem, North Carolina, United States
- Erie, Pennsylvania, United States
- Arlington, Texas, United States
- Lynchburg, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Walnut Creek, California, United States; Winston-Salem, North Carolina, United States; Erie, Pennsylvania, United States; Arlington, Texas, United States; Lynchburg, Virginia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.